New York state sued Purdue Pharma LP, accusing the OxyContin maker of widespread fraud and deception in the marketing of opioids, and contributing to a nationwide epidemic.
Current health systems built to evaluate and pay for traditional drugs are going to struggle with gene and other unusual therapies – but manufacturers can take steps before launch to define how manufacturers assess and value these new products.
The names of the tools may be changing, but the goal for brand managers remains the same in 2018: getting as close as possible to real patients and their needs.
As more innovative – yet even more expensive – therapies enter the U.S. market, brand marketers will have to find equally new and innovative ways to prove the value of their medicines to payers and patients, especially as insurance plans continue to put more of the cost burden on patients.
Executives from 2017 Manny Award winners/finalists and other healthcare communications agencies participated in this Q&A forum of industry topics.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
Two have been around in the pharmaceutical industry for a long time, and one is a relative newcomer. In considering this year’s pharma innovators to profile, the results of their accomplishments, not how long they have been around, steered the direction of this feature. Donna Murphy, global CEO of the recently formed agency network Havas Health & You; Abraham Gutman, president and CEO of AG Mednet; and C. David Nicholson, executive VP and chief R&D officer of Allergan, are being saluted for bringing new innovations to the fields of pharmaceutical advertising, clinical trial imaging and R&D, and their accomplishments are expected to echo into the future.
Collaboration partners Evotec AG and Haplogen GmbH announced that Haplogen will enter into a multi-year drug discovery and development deal with Bayer AG to focus on pulmonary diseases.
Outcome Health Announces Partnership with American Liver Foundation to Promote Updated Screening Recommendations for Hepatitis C
Outcome Health announced a partnership with the American Liver Foundation to raise awareness of liver disease, specifically hepatitis C.
Orchard Therapeutics raised a further $150 million to fund the biotech company’s work in gene therapy, building on earlier fundraisings worth more than $140 million.
Astellas Pharma Inc. plunked down nearly $109 million to snap up privately held Quethera Ltd. and the gene therapy company’s novel treatments for glaucoma and other ocular disorders.
Artios Pharma received a financial boost from Pfizer, AbbVie and Novartis through an $84 million (£65 million) Series B funding.
Gemphire Plunges After Investigational Drug Worsens Liver Fat Levels in Pediatric NAFLD Trial Patients
Shares of Gemphire Therapeutics crashed 73 percent in premarket trading after the company revealed its mid-stage non-alcoholic fatty liver disease treatment for pediatric patients actually worsened the disease in some patients.
GW Pharmaceuticals revealed a $32,500 price for the company’s cannabis-based epilepsy drug Epidiolex.
Boston Scientific Corp. forked over up to $160 million to acquire California stent maker Veniti Inc. The deal marks the third acquisition for Boston Scientific in two months.
AstraZeneca agreed to settle two lawsuits brought by the state of Texas claiming that the drugmaker fraudulently marketed the antipsychotic drug Seroquel and Crestor for high cholesterol.
Sales of some of Novo Nordisk’s key drugs in second-quarter 2018 fell short of expectations and the drugmaker said prices in the key U.S. market would be lower in 2019.
Mark Emalfarb – founder, chairman and chief executive officer of Jupiter, Florida-based Dyadic International – believes he knows how to revolutionize biopharma manufacturing.
Akouos Raises $50 Million Series A Financing and Expands Team to Advance Precision Genetic Therapies That Restore and Preserve Hearing
Akouos, a precision genetic medicine company developing gene therapies that restore and preserve hearing, today announced that the company raised $50 million in Series A financing.
Changsheng Bio-technology Co. Ltd. – a vaccine maker at the center of a safety scandal in China – began falsifying production records for its rabies vaccine in April 2014, state news agency Xinhua reported.
The Business Journals compiled a list of the 25 companies across the United States with the highest median salary for employees, and more than half were in the pharma or biotech industries.
Regeneron Pharmaceuticals Inc. will invest $100 million in cancer drug developer bluebird bio Inc., and the companies will jointly develop new cell therapies for cancer.
August 06, 2018 07:30 ET | Source: VIVUS, Inc. CAMPBELL, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) — VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced the appointment of Ken Suh to the position of President. Previously, Mr. Suh was President and CEO of Willow Biopharma Inc., a wholly-owned subsidiary of […]
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium – consisting of Imperial College London and the Universities of Oxford and Edinburgh – Imperial Innovations, and Oxford BioMedica announced a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis.
Impact Therapeutics, headquartered in Nanjing, China, completed a Series C financing round worth $30 million. The round was led by Decheng Capital with participation from Lilly Asian Ventures.
The Spanish pharmaceutical company Almirall agreed to buy five dermatology brands from U.S. company Allergan for up to $650 million in cash.